EDESA BIOTECH INC (EDSA) Fundamental Analysis & Valuation
NASDAQ:EDSA • CA27966L3065
Current stock price
5.82 USD
-0.04 (-0.68%)
At close:
5.86 USD
+0.04 (+0.69%)
After Hours:
This EDSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. EDSA Profitability Analysis
1.1 Basic Checks
- EDSA had negative earnings in the past year.
- EDSA had a negative operating cash flow in the past year.
- EDSA had negative earnings in each of the past 5 years.
- In the past 5 years EDSA always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of EDSA (-53.13%) is comparable to the rest of the industry.
- EDSA has a better Return On Equity (-56.01%) than 61.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.13% | ||
| ROE | -56.01% | ||
| ROIC | N/A |
ROA(3y)-135.86%
ROA(5y)-111.64%
ROE(3y)-205.71%
ROE(5y)-157.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- EDSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. EDSA Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, EDSA has more shares outstanding
- Compared to 5 years ago, EDSA has more shares outstanding
- EDSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 31.44 indicates that EDSA is not in any danger for bankruptcy at the moment.
- The Altman-Z score of EDSA (31.44) is better than 93.26% of its industry peers.
- There is no outstanding debt for EDSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 31.44 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- EDSA has a Current Ratio of 16.82. This indicates that EDSA is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 16.82, EDSA belongs to the top of the industry, outperforming 94.03% of the companies in the same industry.
- A Quick Ratio of 16.82 indicates that EDSA has no problem at all paying its short term obligations.
- EDSA has a better Quick ratio (16.82) than 94.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.82 | ||
| Quick Ratio | 16.82 |
3. EDSA Growth Analysis
3.1 Past
- EDSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.50%, which is quite impressive.
EPS 1Y (TTM)38.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 7.10% on average over the next years.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.76%
EPS Next 2Y10.67%
EPS Next 3Y2.61%
EPS Next 5Y7.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. EDSA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for EDSA. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDSA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.67%
EPS Next 3Y2.61%
5. EDSA Dividend Analysis
5.1 Amount
- EDSA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EDSA Fundamentals: All Metrics, Ratios and Statistics
5.82
-0.04 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2026-02-13/amc
Earnings (Next)05-12 2026-05-12
Inst Owners36.57%
Inst Owner Change6.12%
Ins Owners12.47%
Ins Owner Change6.46%
Market Cap48.60M
Revenue(TTM)N/A
Net Income(TTM)-7.82M
Analysts82.5
Price Target11.22 (92.78%)
Short Float %20.36%
Short Ratio0.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.68%
Min EPS beat(2)-17.65%
Max EPS beat(2)39%
EPS beat(4)3
Avg EPS beat(4)7.14%
Min EPS beat(4)-17.65%
Max EPS beat(4)39%
EPS beat(8)6
Avg EPS beat(8)6.78%
EPS beat(12)10
Avg EPS beat(12)16.9%
EPS beat(16)14
Avg EPS beat(16)22.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)39.71%
EPS NQ rev (3m)8.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.48 | ||
| P/tB | 4.05 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0
BVpS1.67
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.13% | ||
| ROE | -56.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-135.86%
ROA(5y)-111.64%
ROE(3y)-205.71%
ROE(5y)-157.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.82 | ||
| Quick Ratio | 16.82 | ||
| Altman-Z | 31.44 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y16.76%
EPS Next 2Y10.67%
EPS Next 3Y2.61%
EPS Next 5Y7.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.34%
OCF growth 3YN/A
OCF growth 5YN/A
EDESA BIOTECH INC / EDSA Fundamental Analysis FAQ
What is the fundamental rating for EDSA stock?
ChartMill assigns a fundamental rating of 3 / 10 to EDSA.
Can you provide the valuation status for EDESA BIOTECH INC?
ChartMill assigns a valuation rating of 0 / 10 to EDESA BIOTECH INC (EDSA). This can be considered as Overvalued.
What is the profitability of EDSA stock?
EDESA BIOTECH INC (EDSA) has a profitability rating of 1 / 10.
Can you provide the financial health for EDSA stock?
The financial health rating of EDESA BIOTECH INC (EDSA) is 8 / 10.
Can you provide the expected EPS growth for EDSA stock?
The Earnings per Share (EPS) of EDESA BIOTECH INC (EDSA) is expected to grow by 16.76% in the next year.